Understanding the Clonal Origin of Essential Thrombocythemia

Molecular Mechanisms Behind Clonal Expansion

Some of the most important molecular abnormalities associated with clonal expansion of ET are mutations in the JAK2 gene, which codes for a tyrosine kinase that is essential in cytokine signaling. The JAK2 V617F mutation, which is present in 50–60% of ET patients, results in constitutive activation of the JAK-STAT pathway, which in turn stimulates cell growth and survival irrespective of the cytokines.

Besides the JAK2 V617F mutation, there are other molecular abuses such as CALR, MPL, and so on found in the ET mechanism. CALR mutations are observed in approximately 25% of ET patients and correlate with a particular phenotype of the disease with a rather low thromboembolic risk when compared to JAK2-mutated ET. MPL mutations that affect the thrombopoietin receptor are relatively rare, with the incidence being 5-10%. These mutations also cause activation of the JAK-STAT pathway, thus adding to the clonal expansion process.

The Role of Megakaryocytes and Plapathway, ET

In ET, megakaryocytes, the precursor cells of platelets, possess an enhanced responsiveness to TPO, the most sensitive cytokine in charge of platelet formation. Such hypersensitivity is modulated by the inherent clonal mutations in the disease, especially in the JAK-STAT pathway. Hence, even a small amount of thrombopoietin triggers an abnormally high response in the production of megakaryocytes as well as platelets.

Platelets of ET patients are counted in numbers and size more than those of normal individuals, and higher proliferation of megakaryocytes is found in ET patients, resulting in the overproduction of platelets. However, unlike the platelets seen in most other thrombocythemic disorders, these platelets are frequently functionally impaired, and thus ET patients are at increased risk for thrombosis as well as hemorrhage. The pathophysiology of ET is due to the abnormal connection the body’s platelets have and how they presumably function as individuals; signaling pathways that handle their activation and aggregation are changed. results

Diagnostic Implications of Clonal Expansion

Clonal mutation presence in ET has proved to advance the diagnostic process of the disease. ET was previously diagnosed only after all the other thrombocytosis causes have been excluded, which include reactive thrombocytosis or other MPNs. Despite these, more objective criteria for diagnosing ET have been realized with the identification of specific genetic mutations, which include JAK2 V617F, CALR, and MPL.

Recent studies indicated that routine molecular studies identifying these mutations have become a mandatory component of the preliminary work-up of ET, and the detection of one of these mutations can substantiate the diagnosis in the vast majority of patients. However, around one-tenth to one-fifth of the ET patients are “Triple Negative,” where JAK2, CALR, and MPL mutations are not identifiable. In such circumstances, ET diagnosis is made clinically and through laboratory studies with consideration given to increased platelet count, bone marrow megakaryocytic proliferation, and other known causes of thrombocytosis.

Distinguishing ET from Other Myeloproliferative Neoplasms

One of the difficulties of diagnosing and managing ET is the differentiation of the disease from other categories of MPNs, including polycythemia vera (PV) and primary myelofibrosis (PMF). PV and PMF are clonal myeloproliferative diseases whereby the bone marrow stem cells are mutated; they are related to ET in that they are characterized clinically and in the laboratory by platelet thrombocytosis and JAK2 mutation.

However, there are some differences between these disorders. In PV, the clonal stem cell probably not only induces an increase in the MK series but also in the erythrocytic and granulocytic series with increased RBC and WBC count along with platelets. However, ET is overwhelmingly a disease of the megakaryocytic lineage, and thus patients usually do not have significant anemia or leukocytosis.

ET is defined by the presence of increased numbers of megakaryocytes and granulocytes in the bone marrow, but in contrast to PMF, there is no bone marrow fibrosis, a normal or slightly elevated platelet count, and little evidence of anemia, splenomegaly, or constitutional symptoms. ET is sometimes known to progress into PMF, although, at the time of diagnosis, the two are different.

Treatment Approaches in Essential Thrombocythemia

This means that the management of essential thrombocythemia is focused on the prevention of risks of thrombosis and bleeding in addition to headaches and vertigo. The strategy of management of the patient with HIT depends on characteristics such as age, history of thrombosis, platelet count, etc.

In low-intermediate-risk patients, there are few options, as these are usually young patients with no previous history of thrombosis and a platelet count of fewer than 1,50,000 per µL. Moderate-risk patients are treated with low-dose aspirin to keep the risk of thrombosis low. Patients with one or several risk factors, such as age over 60, history of thrombosis or other coagulation abnormalities, or platelet count above 1000 thous./micro, often require cytoreductive therapy to reduce the risk of complications, and platelet count is often the target of cytoreduction.

Hydroxyurea is the most popular CMA used in ET, and it has been demonstrated to lower the risk of thrombosis in high-risk individuals. Other cytoactive agents have also been applied as anagrelide and interferon-alpha in some situations. Anagrelide selectively inhibits megakaryopoiesis, and interferon-alpha has options for modulatory effects that may be useful in the management of clonality in HSCs.

In MT-CALR-positive patients, data is supporting the notion that patients with MT-CALR are less likely to develop thrombotic events than patients with JAK2 mutation. Therefore, treatment strategies in CALR-mutated ET may be less invasive, with a larger emphasis on regular follow-up and aspirin use rather than early use of aggressive measures to reduce cell mass.

Prognosis and Long-Term Outlook

In general, essential thrombocythemia is regarded to be less aggressive than other MPNs, such as polycythemia vera and PMF. Patients with essential thrombocythaemia can have long survival of up to 10-15 years if adequately managed, and hence the risk of developing acute leukemia is low, with the estimate being 1-2% at 10 years.

Still, over time, some of the patients with ET may progress to myelofibrosis or secondary acute myeloid leukemia. They have also found that patients having MPL or JAK2 mutations, those with a higher platelet count, and elderly patients seem to be at a higher risk of progressing to a higher stage.

Conclusion

Essential thrombocythemia is an inherited disease beginning from a single stem cell in the bone marrow that has the propensity to produce increased platelets. Knowledge of the molecular basis of such clonal expansion, especially concerning JAK2, CALR, and MPL, has greatly improved the diagnosis and treatment of ET. Patients with ET can have a long life expectancy when properly managed; nonetheless, there is a need for other studies that would further elaborate on the long-term effects of ET and research on more specific treatment for this chronic myeloproliferative neoplasm.

References

1. Fialkow, P.J., Faguet, G.B., Jacobson, R.J., Vaidya, K. and Murphy, S., 1981. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell.
2. Axelrad, A.A., Eskinazi, D., Correa, P.N. and Amato, D., 2000. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood, The Journal of the American Society of Hematology, 96(10), pp.3310-3321.
3. Li, Y., Hetet, G., Maurer, A.M., Chait, Y., Dhermy, D. and Briere, J., 1994. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM‐CSF. British journal of haematology, 87(3), pp.471-476.
4. Deininger, M.W., Goldman, J.M. and Melo, J.V., 2000. The molecular biology of chronic myeloid leukemia. Blood, The Journal of the American Society of Hematology, 96(10), pp.3343-3356.
5. Saharinen, P. and Silvennoinen, O., 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. Journal of Biological Chemistry, 277(49), pp.47954-47963.
6. Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I. and Fernández-Luna, J.L., 1998. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. New England Journal of Medicine, 338(9), pp.564-571.
7. Adamson, J.W., Fialkow, P.J., Murphy, S., Prchal, J.F. and Steinmann, L., 1976. Polycythemia vera: stem-cell and probable clonal origin of the disease. New England Journal of Medicine, 295(17), pp.913-916.